drugset / Trial / NCT01508117

Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients

NCT01508117

Phase 2 Terminated 1 enrolled University of Cincinnati Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the addition of an investigational medication, axitinib, to radiation therapy will improve the outcome of treatment in patients, above the age of 70.

Timeline

Start
2011-08
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg

Indications